

Media Contact:
Jan Richardsson
Dignitana Chief Executive Officer
+ 46 46 16 30 92
Jan.Richardsson@dignitana.se



DEMAND FOR DIGNICAP® IS STRONG AS DIGNITANA BRINGS FDA-CLEARED MEDICAL SCALP COOLING DEVICE TO MORE U.S. CANCER CENTERS

Lund, Sweden—June 10, 2016—Dignitana AB, a world leader in medical scalp-cooling technology, announced today that the DigniCap® scalp cooling system, which was recently cleared by the FDA to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now or will soon be available at 26 cancer treatment centers across the U.S.

The DigniCap® scalp cooling system is the first and only scalp cooling device to complete rigorous FDA clinical trials in the U.S., where seven out of ten patients with early-stage breast cancer kept at least 50% of their hair.

Following FDA Clearance in December 2015, medical centers across the country have begun offering the DigniCap scalp cooling system as part of the comprehensive cancer care treatment services they provide. Through funding from a recent Private Placement and Rights Offering, Dignitana is rapidly expanding its reach across America as demand for the medical device accelerates. Agreements with 26 centers have now been signed*, with some of the early adopters ordering additional units within months of initial set up.

To date, Dignitana has announced installations of the DigniCap® scalp cooling system at the following U.S. medical centers: [Bronson Battle Creek Cancer Care Center](#), [Charleston Hematology Oncology Associates](#), [Chesapeake Oncology and Hematology Associates](#), [Florida Cancer Specialists & Research Institute](#), [Menorah Medical Center](#), [Mount Sinai Beth Israel Cancer Center](#), [Mount Sinai Comprehensive Cancer Center](#), [Oncology & Hematology Specialists](#), [Orange County Blood and Cancer Care](#), [The Dubin Breast Center at The Mount Sinai Hospital](#), [Toledo Clinic Cancer Center](#), [Stamford Health Bennett Cancer Center](#), [UCSF Helen Diller Family Comprehensive Cancer Center](#), [UT Health Science Center San Antonio's Cancer Therapy & Research Center](#), and [Wake Forest Baptist Medical Center](#).

The following cancer treatment centers are the most recent U.S. sites to include the DigniCap® scalp cooling system as part of their breast cancer treatment care services:

- [Hematology Oncology Consultants, a Division of Michigan Healthcare Professionals](#)
Royal Oak, Michigan
- [UCHealth's University of Colorado Hospital](#) and [University of Colorado Cancer Center](#)
Aurora, Colorado
- [UCHealth Lone Tree Health Center](#)
Lone Tree, Colorado
- [The C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital](#)
Norwalk, Connecticut
- [Weill Cornell Medicine](#) and [NewYork-Presbyterian](#)
New York, New York
- [The START Center for Cancer Care](#)
San Antonio, Texas

“We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests,” said **Jan Richardsson, Chief Executive Officer of Dignitana**. “From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that

* Five sites not listed have chosen to wait until the DigniCap® system has been installed and is in service before disclosing identity

DigniCap is filling an important need in quality of life cancer care and medical centers are [eagerly promoting](#) its addition to their cancer services.”

The DigniCap® scalp cooling system features a patented tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit with touch screen prompts. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. The cap is fitted to the head, and the temperature of the scalp is lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp, as well as reduced cellular uptake of drugs due to decreased intra follicular metabolic rate. These factors together reduce the risk of chemotherapy-induced hair loss.

About Dignitana AB (publ)

Dignitana is a Swedish public company, based in Lund, and manufacturer of the medical cooling device DigniCap®. Dignitana is continuously researching and developing new uses for DigniCap®. Dignitana AB is listed on the OMX Nasdaq First North stock exchange and has appointed Erik Penser Bank as Certified Adviser. For more information visit www.dignitana.se

###